Last year, the stock declined 62.6%, significantly underperforming the S&P 500 Index’s ($SPX) gain of 25%. Moderna reported ...

Moderna (NASDAQ:MRNA) took a hit Tuesday as Barclays downgraded the stock from Overweight to Equal Weight, citing policy ...

Explore the evolution of vaccine technology from Jenner to mRNA, highlighting India's role in COVID-19 vaccine development.

Barclays downgraded Moderna (NASDAQ:MRNA) to Equal Weight from Overweight in a note Tuesday, citing policy risks, a lack of major clinical catalysts, and macroeconomic uncertainties that limit the ...

Q4 2024 Earnings Call Transcript February 14, 2025 Moderna, Inc. misses on earnings expectations. Reported EPS is $-2.91 EPS, ...

Barclays downgraded Moderna (MRNA) to Equal Weight from Overweight with a price target of $45, down from $111, post the Q4 report. The firm ...

Nanoparticle characterization is vital for mRNA vaccine efficacy, ensuring safety and regulatory compliance in the ...

Millie, a modern maternity clinic, secured $12 million in Series A funding led by existing investors RH Capital, TMV, ...

Moderna designed the final version of its vaccine within 48 hours of analyzing the virus ... In a similar vein, BioNTech was able to rapidly redirect its mRNA technology platform from cancer to ...

Musk's tweet comes against the backdrop of an executive order signed by US President Trump, prohibiting federal funding for ...

were working with a platform for vaccine candidates that had already been tested against other infectious diseases. By contrast, mRNA vaccines developed by Moderna and BioNTech had to be developed ...

Moderna reported phase 3 results with ... based Afrigen Biologics to support the development of an mRNA vaccine technology platform for low- and middle-income countries (LMICs) worldwide.